Pharmacokinetic Study in Healthy Male Volunteers Clinical Trial
Official title:
A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Male Participants to Determine the Effect of an Inhibitor of Cytochrome P450 3A and P Glycoprotein on Exposure to Orvepitant
A Phase 1 study to assess the effect of itraconazole, a strong inhibitor of CYP3A and
P-glycoprotein, on the pharmacokinetics (PK) of orvepitant in healthy male volunteers.
Subjects will receive two single doses of 20mg orvepitant, once alone and once in combination
with repeat doses of itraconazole. All subjects will follow the same sequence - orvepitant
alone followed by orvepitant in combination with itraconazole.
n/a